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1. Abstract 
Background: Lung cancer is a leading cause of cancer death in men and women worldwide. 
In the past decade efforts were made to improve lung cancer therapy. New 
chemotherapeutic agents and several targeted drugs have been introduced. But outcome 
remains poor with an overall five-year relative survival rate less than 20%. Therefore new 
treatment approaches are needed. Several studies have suggested that standard treatment 
in combination with immunotherapy could be more effective. Cancer testis (CT) antigens 
seem to represent promising immune targets and have been tested in multiple vaccine 
formulations. 
Purpose: The aim of this study was to define a non-small cell lung cancer (NSCLC) patient 
population for a multivalent NY-ESO-1, CT7/MAGE-C1-, and CT10/MAGE-C2 vaccine. 
Method: Two consecutively acquired cohorts of NSCLC specimens from chemotherapy 
naïve or treated patients were collected at the Surgical Pathology in Zurich over the course 
of 9 years. In a first cohort, consecutive surgically resected NSCLC patients, who have not 
received chemotherapy yet, were included. In a second, smaller cohort patients who had 
received chemotherapy were analyzed. Considered histologies were adenocarcinoma, 
squamous cell carcinoma, and adeno-squamous carcinoma of the lung. A patient database 
with clinical and pathological characteristics was setup from all collected specimen. Two 
tumor cores of each specimen were immunohistochemically stained for the CT antigens NY-
ESO-1, CT7/MAGE-C1, and CT10/MAGE-C2. Expression frequency and co-expression of 
the CT antigens as well as the proliferation rate was analyzed. Further the expression of CT 
antigens was correlated with clinical and pathological characteristics and the CT antigen 
expression was compared between the chemotherapy naïve and treated patient tumor 
specimens. 
Results: The examined CT antigens were expressed in a coordinated manner. Overall 
CT10/MAGE-C2 was the most frequently expressed CT antigen. In a subgroup analysis 
squamous cell carcinomas were found to express NY-ESO-1 at a significantly higher rate 
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than adenocarcinoma and adeno-squamous carcinomas. Tumors after chemotherapy had 
significantly higher expression of CT7/MAGE-C1. Further CT antigens tend to be expressed 
more frequently in tumors with higher pathological grade or proliferation rate.  
Conclusion: Based on these results a multivalent vaccine including NY-ESO-1, CT7/MAGE-
C1, and CT10/MAGE-C2 could be used in patients with squamous cell carcinoma of the lung 
after or in conjunction with chemotherapeutic treatment. The detected correlation between 
the proliferation rate and CT antigen expression leads to the suggestion that CT antigens 
may play a role in better evaluation of prognosis in the future. As the expression of CT 
antigens is associated with particular tumor types, a refined selection of patients for future 
clinical trials could lead to better results.  
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2. Introduction 
Lung cancer is the leading cause of cancer death in men worldwide and women in developed 
countries. The main risk factor for developing lung cancer is smoking. Eighty percent of all 
smoking related cancer deaths apply to lung cancers. [1-4]. 
Non-small cell lung cancer (NSCLC) encompasses various tumors including the two most 
frequent histologies: 1.) adenocarcinoma and-, 2.) squamous cell carcinoma. Chemotherapy 
and radiotherapy is used before or after surgery for NSCLC patients diagnosed at early 
stages. If inoperable, locally advanced or metastatic NSCLC is diagnosed, treatment typically 
consists of a systemic therapy with platinum-based doublet chemotherapy [5-7]. Patients 
whose tumor carries an epidermal growth factor receptor (EGFR) mutation may benefit from 
initial therapy with EGFR tyrosine kinase inhibitors. If the ROS1 mutation status is positive 
patients can be treated with Crizotinib (tyrosine kinase inhibitor) initially. But the use of 
tyrosine kinase inhibitors is limited due to side-effects/toxicity of the therapy [8-10]. 
Despite the introduction of new chemotherapeutic agents and several targeted drugs in the 
past decade, outcome remains poor with an overall five-year relative survival rate less than 
20% (from 4% for advanced up to 54% for localized stages). Only about 15% of lung cancers 
are diagnosed at early stages. [1, 3] Clearly, new treatment approaches and diagnostic 
options are needed. 
Lung cancer is not typically thought as an “immunogenic” malignancy, but a growing body of 
evidence suggests that immune responses to lung tumors are present in patients, and their 
magnitude may correlate with patient outcome [11-13]. 
The first studies using immunotherapy in lung cancer more than 40 years ago were not 
successful. This lack of success was commonly explained by the poor immunogenicity of 
lung cancers. At that time there was probably in general too little knowledge available about 
immunodeficiency and how to investigate it [14-16]. But even recent studies show a very low 
objective response rate to lung cancer vaccines (2.6%) [17]. This could be explained by an 
insufficient number of immune cells capable of recognizing tumor antigens, absent/or 
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incorrect status of activation of the immune cells at tumor side, or wrong application form. A 
more direct presentation of antigens to T-cells at tumor side possibly enhances the efficiency 
of immune reaction and fastens the immunogenic reaction. Macrophage invasion to tumor 
side is stimulated by hypoxia. Distribution of drugs in hypo-vascularized tumors often is poor. 
If macrophages could be used as a transport system, the drugs could be applied more 
targeted [18]. Nevertheless a vaccine would be a very attractive therapy form because 
opposite to chemotherapy and radiation it allows a more targeted therapy with long term 
effect by memory cells. Furthermore a vaccine is easy to apply and generally has few side 
effects [19, 20]. 
Since the earliest studies knowledge about immunotherapy, tumor environment, and 
potential target proteins has grown to a greater extent. It is evident that the immune system 
is able to recognize tumor-specific antigens, which are unique to the tumor, or an 
overproduction of tumor associated antigens, which can be detected in healthy people as 
well but are differently expressed in tumors (quantity/time/location) [21, 22]. It is important to 
take in account that the vaccination induced immune-response targets only the antigens 
produced at tumor site and can’t destroy healthy cells expressing the same antigens and 
thereby provoke a relevant autoimmune reaction. Further, a mutation in antigen expression 
by the tumor cells would lead to a loss of target and thus be fatal. Last the vaccine should be 
broadly available and applicable [21]. 
The immune-system is able to protect the host from tumor progression up to a certain level. 
Vice versa the tumor is able to escape from immune response by modifying specific 
mechanism: in NSCLC for example by producing TGF-b (tumor growth factor) [23], 
interleukin-10 (probably by inhibiting the production of pro-inflammatory molecules) [24, 25], 
a down regulation of HLA I (human leukocyte antigen) [26, 27], or a lack of maturation of 
dendritic cells after capturing dying tumor cells leading to tolerance [22]. 
The so called “immuno-editing” describes the interaction of tumor- and immune cells in 
relation to metastatic potential, angiogenesis, invasiveness and matrix degradation and 
consists of the three phases: elimination (protection), equilibrium and escape (progression) 
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[21, 28]. For example angiogenesis, which is activated trough a local increase of activity of 
angiogenic factors, such as interleukin-8 and macrophages, is very important for tumor 
growth, metastasis and invasion by providing nutrition, oxygen and an exit route for 
metastasizing cells [18, 29, 30]. Macrophage density at tumor site correlates with interleukin-
8 expression, which itself is positively correlated with micro-vessels forming, metastatic 
potential/distant lymph node metastases and poor prognosis of NSCLC patients [18, 29-31]. 
As angiogenesis is crucial to cancer growth, efforts are made to develop antibodies to 
vascular endothelial growth factors (VEGF) [32]. 
According to Kikuchi et al a significantly decreased number of CD8 positive cells were 
detected in tumor nests of HLA class I negative tumors, wherefore the immune system fails 
to recognize tumor cells. This loss of T-cell toxicity is related to poor prognosis in early 
stages of NSCLC and could be considered as an independent prognostic factor [26].  
In the situation of immunogenic allograft rejection an extensive T-cell infiltration can be 
observed [19]. Several studies have shown that higher tumor infiltration with CD4+ and/or 
CD8+ T-cells in cancer nests is associated with better survival in NSCLC [12, 27, 33]. 
Prognosis seems to be affected by the number and distribution of infiltrating immune cells 
[27, 31]. Interestingly, high CD8+ T-cell infiltration into cancer nests was associated with 
squamous cell histology [27]. In summary the presence or absence of T-cells in the resected 
tumor seems to predict more precisely the clinical outcome than tumor stage and nodal 
status. Therefore the immune response should be taken into account for prognostic 
evaluation and treatment decision [21]. 
But where does the activation of specific immune response take place? Bronchus lymphoid 
tissue (BALT) can normally be observed in fetus and infant lung as well as in inflammatory 
lung disease. Dieu-Nosjean et al investigated that tertiary lymphoid structures can be found 
in tumors (tumor induced (Ti-) BALT), which most likely are induced trough a response to 
tumor micro-environment. Thus the first step in immune response may take place at the 
tumor site itself, largely mediated by the dendritic cells of the Ti-BALT. Little numbers of 
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dendritic cells positively correlate with missing Ti-BALT, leading to a decreased number of 
CD4 cells, poor prognosis, poor T-cell priming and therefore inefficient immunity [34]. 
Cancer testis (CT) antigens represent promising immunization targets in different types of 
cancer and have been tested in multiple vaccine formulations [35, 36]. The proteins are silent 
in healthy adult tissues except in testis, ovary, and placenta without expression of HLA class 
I, and are aberrantly expressed in cancers. Cancer patients show spontaneous immune 
responses against various CT antigens making them an ideal target with little potential of 
autoimmune reaction [37-41]. The expression profile may differ substantially in different 
ethnical groups [38]. Tajima et al for example report a poor expression of NY-ESO-1 in a 
Japanese study-population [41]. Further CT antigens are usually expressed in a coordinated 
manner. Thus a polyvalent vaccine would be preferable in order to increase the eligible 
number of patients [40-42]. More than 100 CT antigens have been detected but only 19 
thereof are capable to generate an immune response [35]. According to Kim et al an 
expression of at least one CT antigen could be detected in about 73% of lung cancer patients 
[35]. In various studies the correlation between CT antigen expression, and pTNM stage, 
grade, cancer histology, gender and age was investigated with divergent results [35, 37, 39, 
43, 44]. It seems that CT antigen expression is more frequent in high grade tumors. 
Therefore CT antigens could play a role in better evaluation of prognosis [37]. 
The melanoma-associated antigen 3 (MAGE-A3), which is more frequently expressed in 
squamous cell carcinoma, than in adenocarcinoma [39], has been evaluated in multiple 
vaccine formulas [45, 46]. MAGE-A3 in combination with an immune-stimulant is currently 
being evaluated as a vaccine in a randomized, double-blinded, placebo-controlled phase III 
trial in an adjuvant setting after completely surgical resection of early-stage (IB, II and IIIA) 
MAGE-A3 positive NSCLC (MAGRIT). Some of this patients received chemotherapy. 
Whereas only chemotherapy naïve patients with tumor stage IB to II were included in the 
phase II study. In this smaller study-group no advancement in the disease-free-interval could 
be found and thereby the primary endpoint was not met [45]. According to the ESMO 
(European Society for Medical Oncology) congress press release 2014 the results of the 
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phase III are as well disappointing. No improvement of disease-free survival could be 
detected in the setting of simultaneous neo-adjuvant chemotherapy administration. The 
abstract of the study is available on the ESMO website [47]. 
Another vaccine formulation CV9202 RNActive®, which consists of six different components, 
among them NY-ESO-1, CT10/MAGE-C2 and CT7/MAGE-C1, is currently being tested in a 
phase I trial for patients with stage IV NSCLC [48]. 
Recently evidence emerged that immunotherapy in combination with radio- or chemotherapy 
is more effective. Different studies illustrated that the expression of cancer testis antigens 
increases with radiotherapy and through this the immunogenicity of tumors increases as well 
(γ-Radiation promotes immunological recognition of cancer cells through increased 
expression of cancer-testis antigens in vitro and in vivo) [14, 22, 49-51]. Demaria et al 
describe the relation between radiation and immune answer as fallowing: trough radiation the 
production of “danger” cells, release of pro-inflammatory cytokines (interleukin-1b, TNF-alpha 
(tumor necrosis factor)), and of prostaglandin E and HLA I increase. A change in tumor 
microenvironment and vessels was observed as well. The endothelial cells express an 
adhesion molecule, which is different in tumor and normal vessels and might increase the T-
cell invasion at tumor side [22]. Older studies also showed that transferring T-cells after 
provoked lymph depletion trough radiation is more effective because of a change in quality 
and impact (for example by elevated production of interleukin-2, TNF-alpha) rather than by 
their quantity [52]. Recently, antibody-facilitated T-cell induction in cancer was tested. A 
monoclonal antibody (mAB) against CT antigens was added and the local release was 
prompted by chemo- or radiotherapy. The complex of mAB and CT antigen was then 
presented to dendritic cells more easily and leaded to a boosted activation of CD8 T-cells 
[51]. 
Due to antigenic heterogeneity and potential for immune escape effective anticancer 
vaccines should try to include multicomponent and -valent rather than single or oligo-
component vaccines and to combine the immunotherapy with agents capable to block 
factors, which are diminishing the antitumor answer [14, 21]. For example myeloid 
7 
 
suppressor cells (MSC) produced by tumor cells are able to down regulate the elimination of 
the tumor trough T-cells. One enzyme which is needed for MSC function is arginase I. The 
tumor produces prostaglandin E2, which itself stimulates the production of arginase I. A 
therapeutic option could therefore involve a suppression of the arginase I activity with COX-2 
inhibitors which then leads to a down regulation of MSC [53]. 
In summary it seems that vaccination in combination with radio- and/or chemotherapy could 
be a new treatment approach [54]. 
In the present study, we investigated the frequencies of expression and co-expression of the 
three CT antigens, NY-ESO-1, CT7/MAGE-C1, and CT10/MAGE-C2 in a large unselected 
cohort of consecutive surgically resected NSCLC patients. Further we correlated the 
expression of CT antigens with clinical and pathological characteristics. In a second study 
cohort the intensity of CT antigen expression after chemotherapy was observed.  
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3. Patients and methods 
3.1 Data collection 
At the Institute of Surgical Pathology Zurich, n=491 consecutive surgically resected NSCLC 
patients were retrieved from the PathoPro computer files. Data was collected between 
January 1993 to December 2002 from 7 different referral hospitals (University Hospital Zurich 
n=397, Stadtspital Waid n=48, Kantonsspital Zug n=18, Spital Männedorf n=12, Spital Uster 
n=9, Spital Zollikerberg n=6, Klinik im Park n=1). Adenocarcinomas, squamous cell 
carcinomas and adeno-squamous carcinomas were included. Large cell -, combined small 
cell - and pleomorphic carcinoma patients were excluded. 17 patients from the first cohort 
were removed from survival analysis due to lack of data or lethal complications before 30 
days post-surgery (n=474). The cut off was set at 30 days post-surgery to exclude all 
patients with lethal complications not due to tumor progression. In a second cohort 41 
patients after treatment with neo-adjuvant chemotherapy were analyzed.  
Two cores of each patient were stained. If one core out of a pair was lacking tumor 
nevertheless data extraction was carried forward. 
Progression-free survival (PFS) time was defined as the interval between the date of surgery 
and disease progression, death or last contact, respectively. Only documented relapses were 
accepted for warranting progression. During the initial years of data collection a follow-up 
control with PET-CT (positron emission tomography-computed tomography) was not a 
standard procedure to document/search tumor relapse. Therefore patients with initial 
metastatic disease were excluded from PFS calculations (n=432). Overall survival (OS) time 
was defined as the interval between the date of surgery and death or last contact, 
respectively. The end date of the follow-up study was 54 months. The mean duration of the 
follow-up was 43 (range 0-169) and 51 months (range 1-169 months) for PFS and OS, 
respectively. 
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3.2 Ethical issues 
This study was approved by the ethic committee of the University Hospital Zurich (reference 
number StV 29-2009 (attached at the appendix)).  
 
3.3 Tissue microarray (TMA) construction 
The construction of a set of three TMA’s was accomplished with a custom-made, 
semiautomatic tissue arrayer (Beecher Instruments, Sun Prairie, WI, USA). Two tissue cores 
of 0.6 mm in diameter were taken from each case and transferred into the recipient paraffin 
block. Wherever applicable in adenocarcinoma, an area representing the solid growth pattern 
was selected for the first core and a core representing either the glandular, bronchiolo-
alveolar, or papillary pattern for the second (n=982). Cores from appropriate control tissue 
including tonsillar lymphatic parenchyma, normal lung and normal bronchial mucosa were 
added at the end. Four micrometer thick sections were transferred to an adhesive-coated 
slide system (Instrumedics, Hackensack, USA). 
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3.4 Immunohistochemistry 
The expression of NY-ESO-1, CT7/MAGE-C1 and CT10/MAGE-C2 was analyzed 
immunohistochemically. Consecutive 3 µm sections were cut from TMA blocks and mounted 
on glass slides (Super-Frost Plus, Menzel, Braunschweig, Germany). For 
immunohistochemical staining the Ventana Benchmark automated staining system (Ventana 
Medical Systems, Tucson, AZ) and Ventana reagents were used. After deparaffinization in 
xylene, slides were rehydrated in decreasing concentrations of ethanol. Endogenous 
peroxidase was blocked using Ventana endogenous peroxidase blocking kit after a rinse with 
distilled water. For antigen retrieval slides were heated with cell conditioning solution (CC1, 
Ventana) according to manufacturer’s instructions. The primary antibody against 
CT10/MAGE-C2 (rabbit polyclonal, 1:500, ProteinTech Group, Inc.), CT7/MAGE-C1 (clone 
CT7-33, 1:80, DAKO A/S) and NY-ESO-1 (clone E978, 1:50, ZYMED) were applied adjusted 
to the Ventana Benchmark system after performing titrations. iVIEW-DAB was used as 
chromogen. Antibodies were tested on both multi-tissue microassays and whole sections 
from germ cell tumors as positive control. For negative controls, the primary antibody was 
omitted. Non-interpretable results, due to lack of target tissue, presence of necrosis or crush 
artifact, were excluded from analysis. 
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3.5 Interpretation of results 
Immuno-reactivity of all antibodies was scored independently by two investigators 
(investigator one: Prof. Dr. med. A. Soltermann, investigator two: M. Mattle) in a blinded 
manner. The intensity was semi-quantitatively scored 0 (negative), 1 (weak), 2 (moderate) or 
3 (strong) per individual core (figure 1). The percentage of cells having any positivity was 
proportionally scored 0 (0%), 0.1 (1-9%), 0.5 (10-49%) or 1.0 (50% and more).  
 
1       2 
          
 
 
3 
 
 
 
Figure 1: Immunhistochemical fingings for CT10/MAGE-C2 in lung carcinomas.  
1. weak, 2. moderate, 3. strong. 
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3.6 Statistical analysis 
Data was analyzed by two different methods: First, score results were tested by Chi-squared 
associations, a test developed to discover whether there is a significant association between 
two categorical variables. Second, data was analyzed by Kendall’s tau-beta correlations, a 
test developed particularly for small tables and for detecting correlations between non-
parametric data. PFS and OS were calculated by the Kaplan-Meier method and differences 
compared by the log-rank test. The 95% confidence interval (95% CI) was calculated to 
visualize the uncertainty associated with the estimate (95% CI = mean-value ± (1SE 
(standard error) x 1.96)). Analyses were carried out using SPSS 22.0 software package 
(SPSS Inc., Chicago, USA). 
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4. Results 
4.1 Inter-observer variability 
Two cores of each tumor were scored independently by two investigators for the presence of 
NY-ESO-1, CT7/MAGE-C1 and CT10/MAGE-C2 by grading the percentage and intensity. A 
very low inter-observer variability for the collected results (kappa value: 0.955, 0.935 and 
0.989 for CT7/MAGE-C1, CT10/MAGE-C2 and NY-ESO1 respectively) was proved. Thus for 
better clarity further on only the results of investigator one will be illustrated. 
 
4.2 Cohort und demographic parameters 
A total of 491 cases of NSCLC were collected before radio- or chemotherapy. As mentioned 
above 17 patients were excluded from survival analysis (n=474). While most stage III and IV 
patients receive chemotherapy or radiotherapy before surgical reevaluation, stage I and II 
patients are being operated directly, explaining the predominance of this group as shown in 
table 1. The two main histological groups included where adenocarcinomas and squamous 
cell carcinomas. The mean tumor size was 3.7cm. The mean age was 64 years, and 30.8% 
were females (table 1). The mean age and size was used as cut off point for group allocation 
for OS and PFS calculations. The 4.5-year overall- and progression free survival correlated 
with the pTNM stage, age and size of the tumor, but not with the gender (table 2 and 3). For 
example 48% of patients ≤64 years showed a progression free survival compared with 35% 
of the patients >64 years (table 2).  
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Table 1: Cohort parameters 
 
n=474 Number Number% 
Age 
  ≤ 64 y 231 48.7% 
> 64 y 243 51.3% 
Gender 
  Male 328 69.2% 
Female 146 30.8% 
Histotype 
  AC 233 49.2% 
SCC 223 47.0% 
ASQ   18   3.8% 
pT 
  T1   98 20.7% 
T2 259 54.6% 
T3   71 15.0% 
T4   46   9.7% 
pN 
  N0 247 52.1% 
N1 143 30.2% 
N2   75 15.8% 
N3     9   1.9% 
pM 
  M0 432 91.1% 
M1   42  8.9% 
Grade 
  G1    27    5.7% 
G2 244 51.5% 
G3 203 42.8% 
Size 
  ≤ 3.7 cm 235 49.6% 
> 3.7 cm 239 50.4% 
 
Legend: 
AC Adenocarcinoma 
SCC Squamous cell carcinoma 
ASQ Adenosquamous carcinoma 
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Table 2: 4.5-year overall survival rates 
 
n=474 4.5y-OS p-value 95% CI 
Age  
 
 
≤ 64 y 50% 
 
±6.5% 
> 64 y 36% <0.001 ±6.1% 
Gender  
 
 
Male 40% 
 
±5.5% 
Female      49% 0.012 ±8.0% 
Histotype  
 
 
AC 44% 
 
±6.5% 
SCC 43% 
 
±6.5% 
ASQ 33% 0.477 ±17.6% 
pT  
 
 
T1 61% 
 
±10.0% 
T2 45% 
 
±6.1% 
T3 37% 
 
±11.2% 
T4   9% <0.001 ±8.2% 
pN  
 
 
N0 54% 
 
±6.3% 
N1 36% 
 
±8.0% 
N2 25% 
 
±10.0% 
N3   0% <0.001 ±0% 
pM  
 
 
M0 47% 
 
±4.7% 
M1   2% <0.001 ±4.7% 
Grade  
 
 
G1 63% 
 
±18.0% 
G2 47% 
 
±6.5% 
G3 36% 0.023 ±6.7% 
Size  
 
 
≤ 3.7 cm 53% 
 
±6.5% 
> 3.7 cm 34% <0.001 ±6.1% 
 
Legend: 
AC Adenocarcinoma 
SCC Squamous cell carcinoma 
ASQ Adenosquamous carcinoma 
OS Overall survival time = interval between the date of surgery and death or last contact. 
CI Confidence interval 
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Table 3: 4.5-year progression-free survival rates 
 
n=432 4.5y-PFS p-value 95% CI 
Age  
 
 
≤ 64 y 48% 
 
±6.9% 
> 64 y 35% <0.001 ±6.3% 
Gender  
 
 
Male 39% 
 
±5.7% 
Female 46% 0.141 ±8.4% 
Histotype  
 
 
AC 41% 
 
±6.9% 
SCC 43% 
 
±6.7% 
ASQ 11% 0.008 ±18.4% 
pT  
 
 
T1 61% 
 
±10.2% 
T2 41% 
 
±6.3% 
T3 34% 
 
±11.6% 
T4 5% <0.001 ±6.7% 
pN  
 
 
N0 50% 
 
±6.5% 
N1 35% 
 
±6.7% 
N2 23% 
 
±10.4% 
N3 0% <0.001 ±0% 
pM  
 
 
M0 41% 
 
±4.7% 
M1 - - - 
Grade  
 
 
G1 52% 
 
±20.0% 
G2 45% 
 
±6.7% 
G3 34% 0.034 ±6.9% 
Size  
 
 
≤ 3.7 cm 52% 
 
±6.7% 
> 3.7 cm 30% <0.001 ±6.3% 
 
Legend: 
AC Adenocarcinoma 
SCC Squamous cell carcinoma 
ASQ Adenosquamous carcinoma 
PFS Progression-free survival time = interval between the date of surgery and disease progression, 
death or last contact. Initial metastatic diseases were excluded. 
CI Confidence interval 
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4.3 Correlation between frequency of protein expression and clinical/ 
pathological parameters 
Two cores of each tumor were stained in this cohort for the presence of NY-ESO-1, 
CT7/MAGE-C1, and CT10/MAGE-C2. 147/491 patients (29.9%) expressed at least one of 
the three analyzed CT antigens. The most prevalent cancer testis antigen was CT10/MAGE-
C2 with expression in 21% of all cores. CT7/MAGE-C1 was expressed in 16.7% of the cores 
and NY-ESO-1 in 10.2% (table 4). 
 
Table 4: Frequency and intensity of antigen expression (2 cores of each tumor/patient) 
 
Intensity NY-ESO-1 CT7 CT10 
0 89.8% 83.3% 79% 
Core 1    
1 3.1% 4.1% 4.1% 
2 3.1% 3.9% 4.9% 
3 1.8% 3.7% 4.1% 
Core 2    
1 0.6% 1% 1.8% 
2 0.6% 1.4% 2.2% 
3 1% 2.6% 3.9% 
 
Legend:  
0 = no expression 
1 = weak, 2 = moderate, 3 = strong 
 
NY-ESO-1 expression frequency was significantly different between histologic subtypes. NY-
ESO-1 was significantly higher expressed in squamous cell carcinomas and less frequently 
in adenocarcinomas or mixed tumor types (p < 0.001). This expression pattern was not found 
for CT10/MAGE-C2 or CT7/MAGE-C1. 
In addition CT antigen expression generally correlated with grade by univariate analysis for 
CT7/MAGE-C1 and CT10/MAGE-C2 (p-value: 0.021 and 0.109 for CT7/MAGE-C1 and 
CT10/MAGE-C2 respectively), but not for NY-ESO-1 (table 5). When the patients where 
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stratified according to histology as well a correlation between NY-ESO-1 expression and 
grade was observed. 
 
Table 5: CT antigen expression correlated with clinical/pathological parameters 
 
n=491   NY-ESO-1 CT7 CT10 
    Chi Kendall Chi Kendall Chi Kendall 
Age p 0.480 0.385 0.630 0.102 0.308 0.130 
≤/> 64 t  -0.039  -0.071  -0.066 
Gender p 0.204 0.083 0.174 0.827 0.436 0.436 
M/F t   -0.070   0.010   0.034 
Histo p 0.002 0.000 0.053 0.099 0.501 0.803 
A-S-Q t  0.158  0.073  0.011 
pT p 0.668 0.282 0.607 0.734 0.668 0.702 
 t   -0.043   0.013   0.015 
pN p 0.972 0.479 0.812 0.026 0.704 0.297 
0-3 t  -0.028  -0.086  -0.041 
pM1 p 0.328 0.804 0.861 0.487 0.217 0.315 
0-1 t   0.011   0.033   0.047 
Grade p 0.158 0.013 0.021 0.000 0.109 0.000 
 t  0.107  0.172  0.154 
Size p 0.071 0.031 0.138 0.030 0.122 0.203 
≤/> 3.7 t   -0.095   0.094   0.055 
 
Underlined values are statistic significant 
 
Legend: 
p   p-value 
t  Kendall’s tau-beta correlation value 
Chi  Chi-squared associations 
Kendall Kendall’s tau beta correlations 
Histo  Histology 
A-S-Q adenocarcinomas, squamous cell carcinomas, adeno-squamous carcinomas  
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4.4 Cancer testis (CT) antigen expression and overall survival/progression free 
survival  
We could not find a difference in progression free survival or overall survival between 
positive or negative groups of CT7/MAGE-C1, CT10/MAGE-C2 or NY-ESO-1 in the selected 
NSCLC study cohort (table 6, figure 2). 
 
Table 6: Correlation between OS/PFS and CT antigen expression 
 
n=432 4.5y-PFS p-value 95% CI 
CT7 
 
  
negative 42%  ±5.1% 
positive 38% 0.774 ±11.2% 
CT10 
 
  
negative 40%  ±5.3% 
positive 44% 0.251 ±10.4% 
NY-ESO-1 
 
  
negative 41%  ±4.9% 
positive 44% 0.067 ±14.5% 
 
n=474 4.5y-OS p-value 95% CI 
CT7 
   negative 44% 
 
±4.9% 
positive 40% 0.384 ±10.6% 
CT10 
   negative 44% 
 
±5.1% 
positive 41% 0.309 ±9.6% 
NY-ESO-1 
   negative 43% 
 
±4.7% 
positive 42% 0.119 ±13.7% 
 
Legend: 
CI Confidence interval  
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a 
  
b 
  
c 
  
 
Figure 2: Kaplan-Meier survival curves for overall survival and progression free survival. Comparison 
between positive and negative groups of (a) CT7/MAGE-C1, (b) CT10/MAGE-C2, (c) NY-ESO-1 in the 
selected lung cancer patients. Mean duration of the follow-up was 43 (range 0-169) for PFS and 51 
months (range 1-169 months) for OS respectively.  
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4.5 Co-expression of NY-ESO-1, CT7/MAGE-C1 and CT10/MAGE-C2 
A significant co-expression was found for CT7/MAGE-C1 with CT10/MAGE-C2, CT7/MAGE-
C1 with NY-ESO-1 and CT10/MAGE-C2 with NY-ESO-1 (0.581, 0.227 and 0.199, Kendall 
tau-beta correlation respectively, p-value < 0.001) (table 7).  
 
Table 7: Co-expressions 
 
 CT7 CT10 NY-ESO-1 MIB-1 
Kendall-Tau-b CT7 Korrelationskoeffizient 1.000 .581** .227** .200** 
Sig. (2-seitig) . .000 .000 .000 
N 491 490 491 490 
CT10 Korrelationskoeffizient .581** 1.000 .199** .148** 
Sig. (2-seitig) .000 . .000 .000 
N 490 490 490 489 
NY-ESO-1 Korrelationskoeffizient .227** .199** 1.000 .157** 
Sig. (2-seitig) .000 .000 . .000 
N 491 490 491 490 
MIB-1 Korrelationskoeffizient .200** .148** .157** 1.000 
Sig. (2-seitig) .000 .000 .000 . 
N 490 489 490 490 
**. Significant correlation 
 
Legend: 
MIB-1  KI-67 proliferation index, determined using the MIB-1 antibody for staining (discussed  
elsewhere).  
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4.6 Frequency and intensity of CT antigen expression after chemotherapy 
Forty-one patients were operated after neo-adjuvant chemotherapy. The chemotherapy 
consisted of a platinum-based doublet. We found that the expression of CT7/MAGE-C1 was 
more common in the cohort that had received chemotherapy (p < 0.001). As well the intensity 
of CT7/MAGE-C1 expression was higher after chemotherapy (figure 3). The expression of 
CT10/MAGE-C2 and NY-ESO-1 was not statistically relevant affected by the use of 
chemotherapy (p-value: 0.807 and 0.618 for CT10/MAGE-C2 and NY-ESO-1 respectively). 
 
  
 
 
 
 
 
Figure 3: The influence of chemotherapy on CT antigen expression. 
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4.7 Proliferation rate and expression of the investigated CT antigens 
All carcinomas with high CT antigen expression had a high MIB-1 proliferation rate (sum of 
mib expression of core 1 and 2) (table 7). Carcinomas with low proliferation rates have 
shown no expression of CT7/MAGE-C1 or NY-ESO-1. In contrast few carcinomas with low 
proliferation rate did express CT10/MAGE-C2 (figure 4). 
 
 
        
 
 
 
 
 
 
Figure 4: CT antigen expression in relation to the proliferation rate. 
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5. Discussion 
The strength of this study lies within the evaluation of one of the largest series of a NSCLC 
patient cohort. This allows a rigorous analysis of CT antigen expression in NSCLC 
subgroups. We chose immunohistochemistry-based analysis due to the clinical relevance of 
protein expression. We showed that CT10/MAGE-C2 is the most common antigen expressed 
in NSCLC - compared to NY-ESO-1, and CT7/MAGE-C1 and that the examined CT antigens 
are expressed in a coordinated manner. 
CT antigen can be detected by cytotoxic T-lymphocytes and may be destroyed by them, 
leading to the suggestion that the expression of CT antigens is linked to a favorable 
prognosis [39]. Contrary, different studies have demonstrated that the expression of CT 
antigens has a negative impact on survival and is related with an unfavourable prognosis [39, 
42, 44]. In our study we could not observe a correlation between antigen expression and OS 
or PFS. 
The relation between CT antigen expression and clinical and pathological parameters such 
as pTNM stage, grade, histology, size, gender, and age were investigated several times with 
divergent results. According to Kim et al a positive correlation exists between age, gender 
and CT antigen expression, but not with pT and pN Stage or histology [35]. Whereas in a 
subgroup analysis of MAGE genes a correlation between MAGE-A4 expression, size and pN 
stage, as well as between MAGE-A3 expression, advanced tumor and poor outcome, plus 
between MAGE B, -A2, -D2 with pM stage was found [37, 43]. MAGE proteins are linked to 
cancer progression and metastasis partly by suppressing p53 (inhibition of apoptosis). 
Targeting of these cells and destroying them could lead to better prognosis [39]. Further Kim 
et al postulate that NY-ESO-1 is a negative prognostic factor for survival in late stages of 
lung cancers [38]. We found relevant differences in the expression frequency of CT antigens 
and histologic subtypes. NY-ESO-1 was more commonly expressed in squamous cell 
carcinoma and less frequently in adenocarcinomas or mixed tumor types. No correlation was 
found for CT10/MAGE-C2 and CT7/MAGE-C1. We found no association between age or 
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gender and CT antigen expression. In accordance with Caballero et al we could illustrate that 
more aggressive carcinomas, with a high MIB-1 score or a higher pathological grade tended 
to express CT antigens at a higher frequency [36]. 
John et al suppose that NY-ESO-1 is a predictive factor for which patients have a potential to 
benefit from neo-adjuvant chemotherapy [44]. Interestingly, we demonstrated that 
CT7/MAGE-C1 expression was more common in tumors that had been treated with 
chemotherapy. No correlation was found for CT10/MAGE-C2 or NY-ESO-1 expression. In 
previous studies it has been shown that radiotherapy increases the expression of CT 
antigens in vitro on tumor cell lines and tumor explants [14, 22, 49-51]. This study on lung 
cancer patients suggest that a similar effect could be seen for chemotherapies. If capable of 
inducing CT antigen expression in vivo, treatment with CT antigen targeted immunotherapy 
could be applied in all chemotherapy and radiotherapy treated lung cancer patients.  
In conclusion, the fact that the expression of CT antigens is associated with particular tumor 
types and patient cohorts allows a refined selection for future clinical trials. CT antigens could 
not only play a role in immunotherapy but also in better evaluation of prognosis [37]. 
Because there is a strong co-expression among CT antigens, a multi-CT antigen targeting 
strategy would be predicted to be most effective. Moreover, it could be argued that CT 
antigen immunization might be beneficial even to patients with CT antigen -negative tumors, 
as an induced anti-CT antigen immune response might prevent the emergence of CT antigen 
expressing tumor cells, thus halting or slowing tumor progression. In squamous cell 
carcinoma a multivalent vaccine including NY-ESO-1, CT7/MAGE-C1, and CT10/MAGE-C2 
could be considered after or in conjunction with treatment with platinum-based doublet 
chemotherapy.  
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